A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors
Interventions: DRUG: JAB-3312
Sponsor: Jacobio Pharmaceuticals Co., Ltd.